Ask AI
ProCE Banner Activity

PURPOSE 2: Pharmacokinetic Effects of Lenacapavir on Gender-Affirming Hormone Therapy in Gender-Diverse People 

Conference Coverage
Slideset

Among gender-diverse people enrolled on the PURPOSE 2 trial, pharmacokinetics of gender-affirming hormone therapy remained consistent with baseline levels during coadministration of lenacapavir.

Released: October 27, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare